AIDS vaccine advisory committee
An ongoing Phase III study of Aventis-Pasteur's ALVAC vCP-1521 HIV vaccine with VaxGen's AIDSVAX will be discussed at FDA's Vaccines & Related Biologics Advisory Committee's Sept. 23 meeting. The meeting will be held at the Holiday Inn in Bethesda, Md. beginning at 9 a.m. The committee will be closed from 11 a.m. to 12:15 p.m. to discuss trade secret/confidential information [Editor's Note: To 1watch a webcast or order a video/DVD of this meeting, visit FDAAdvisoryCommittee.com.]...
You may also be interested in...
AdvaMed’s VentConnect platform is expanding to support production of devices needed to treat COVID-19. Here’s what Eric Fanning, CEO of participating group the Aerospace Industries Association, said about the move.
Preliminary plans for an Oct. 22 meeting of US FDA's vaccine advisory committee suggest a fast evaluation of COVID-19 immunizations, bringing mixed reactions from onlookers who say it could be a positive sign of needed public transparency or an indication the agency is rushing to approve a product ahead of the November presidential election.
Lawyer asks US FDA to require another trial before licensing Mesoblast’s stem cell therapy for children with SR-aGVHD; Incyte’s Jakafi is only product approved for the indication.